

April 6, 2026

To NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Symbol: AUROPHARMA	To BSE LIMITED Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, MUMBAI -400 001 Scrip Code: 524804
--	--

Sub: Outcome of the meeting of the Board of Directors (“Board”)

Ref: Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“Listing Regulations”).

Dear Sir / Madam,

In continuation of our letter dated March 31, 2026, and in terms of Regulation 30 of Listing Regulations, we wish to inform you that the Board of the Aurobindo Pharma Limited (“**Company**”), at its meeting held today (i.e., April 6, 2026), has inter-alia, considered and approved:

- (i) subject to such approvals of regulatory and/or statutory authorities as may be required under applicable laws, the buyback of up to 54,23,728 (Fifty four lakhs twenty three thousand seven hundred and twenty eight only) fully paid-up equity shares of the Company, each having a face value of INR 1/- (Indian Rupee one only) (“**Equity Shares**”), representing up to 0.93% of the total number of equity shares in the paid-up equity share capital of the Company, at a price of INR 1,475/- (Indian Rupees one thousand four hundred and seventy five only) per Equity Share (“**Buyback Price**”) payable in cash for an aggregate amount up to INR 800,00,00,000/- (Indian Rupees eight hundred crores only) (“**Buyback Size**”) being 3.93% and 2.62% of the aggregate of the total paid-up equity share capital and free reserves (including securities premium) as per the latest audited standalone and consolidated financial statements of the Company as at March 31, 2025, respectively. The Buyback Size does not include transaction costs viz. brokerage costs, fees, turnover charges, applicable taxes on this, securities transaction tax, goods and services tax, stamp duty, etc., and expenses incurred or to be incurred for the buyback like filing fees payable to the Securities and Exchange Board of India (“**SEBI**”), advisors/ legal fees, public announcement publication expenses, printing and dispatch expenses and other incidental and related expenses, etc.

The buyback is proposed to be made from all of the equity shareholders / beneficial owners of the Company, including the promoters and members of the promoter group of the Company (as defined under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011), who hold Equity Shares as of the record date (as mentioned below), on a proportionate basis through the “tender offer” route, in accordance with the provisions contained in the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018, as amended (“**Buyback Regulations**”) and the Companies Act, 2013, as amended and rules made thereunder;

AUROBINDO PHARMA LIMITED

www.aurobindo.com

(CIN : L24239TG1986PLC015190)

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.

Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana., India. Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833

Email: info@aurobindo.com Website: www.aurobindo.com

- (ii) the formation of a buyback committee (“**Buyback Committee**”) and delegated its powers to the Buyback Committee to do all such acts, deeds, matters and things as it may, in its absolute discretion, deem necessary, expedient, usual or proper in connection with the Buyback; and
- (iii) April 17, 2026 (“**Record Date**”) as the record date for the purpose of determining the entitlement and the names of equity shareholders who would be eligible to participate in the buyback, in accordance with Regulation 42 of the Listing Regulations and Regulation 9(i) of the Buyback Regulations.

In terms of Regulation 5(via) of the Buyback Regulations, the Board / Buyback Committee may, till 1 (one) working day prior to the Record Date, increase the Buyback price and decrease the number of Equity Shares proposed to be bought back, such that there is no change in the Buyback Size.

The pre-buyback shareholding pattern as on December 31, 2025 is enclosed as **Annexure A**. Please note that the details regarding the post-buyback shareholding pattern have not been provided since the actual number of Equity Shares that are bought back and category of shareholders from whom the Equity Shares will be bought back can be determined after the Record Date.

The public announcement and the letter of offer setting out the process, timelines, and other requisite details will be released in due course in accordance with the Buyback Regulations.

The relevant details as per SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/ 2026 dated July 11, 2023 and updated on January 30, 2026, are given as **Annexure B**.

We would like to inform you that the said meeting commenced at 7:00 a.m. and concluded at 8:10 a.m .

This is for your information and records.

Thanking you,

For **Aurobindo Pharma Limited**

B Adi Reddy
Company Secretary & Compliance Officer

Encl.: As above

AUROBINDO PHARMA LIMITED

www.aurobindo.com

(CIN : L24239TG1986PLC015190)

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana., India. Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833
Email: info@aurobindo.com Website: www.aurobindo.com

Annexure - A

Pre-buyback shareholding pattern of the Company as on December 31, 2025 is set out below:

S. No.	Shareholder Category	Number of shareholders	No. of equity shares held	% of shareholding
1	Promoters & Promoter Group	14	30,09,48,721	51.82
2	Mutual Funds	39	11,33,67,285	19.52
3	Alternative Investment Fund	16	23,72,269	0.41
4	Banks	2	5,710	0.00
5	Insurance Companies	20	3,19,45,364	5.50
6	Qualified Institutional Buyer	0	0	0
7	Bodies Corporates & NBFCs	1,273	29,73,499	0.51
8	Foreign Portfolio & FIIs	614	8,09,91,628	13.94
9	Non Resident Indians	7,035	21,53,680	0.37
10	General Public and Others	2,27,846	4,60,43,467	7.93
Total		2,36,859	58,08,01,623	100.00

Note: The post buyback shareholding pattern of the Company shall be ascertained subsequently.

For Aurobindo Pharma Limited

B Adi Reddy
Company Secretary & Compliance Officer

AUROBINDO PHARMA LIMITED

www.aurobindo.com

(CIN : L24239TG1986PLC015190)

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.
 Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana., India. Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833
 Email: info@aurobindo.com Website: www.aurobindo.com

Annexure - B

Details as per SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/ 2026 dated July 11, 2023 and updated on January 30, 2026

S. No.	Particulars	Description
1.	Number of securities proposed for buyback	54,23,728
2.	Number of securities proposed for buyback as a percentage of existing paid-up capital	0.93%
3.	Buyback price	INR 1,475/- (Indian Rupee one thousand four hundred and seventy-five only) per equity share
4.	Actual securities in number and percentage of existing paid-up capital bought back	Not applicable
5.	Pre and post buyback shareholding pattern.	Pre buyback shareholding pattern of the Company is provided in Annexure A and the post buyback shareholding shall be ascertained subsequently.

AUROBINDO PHARMA LIMITED

www.aurobindo.com

(CIN : L24239TG1986PLC015190)

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana., India. Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833
Email: info@aurobindo.com Website: www.aurobindo.com